This commercial partnership can benefit all stem cell companies, legitimising stem cell science and technology in both the general public's and regulators' (plural) eyes. Other companies will benefit from this, some people are too short-sighted to see this.
@Sector is (allegedly) a Top 20 holder in CYP - of course he doesn't want to see the alternative view. This dude is wearing out keyboards on the CYP threads re MSB...
Today's announcement is very positive for MSB, and there are some serious SP catalysts potentially just around the corner.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-320
-
- There are more pages in this discussion • 492 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |